Literature DB >> 14499690

Clinicopathologic significance of genetic alterations in hepatocellular carcinoma.

A Pang1, I O Ng, S T Fan, Y L Kwong.   

Abstract

Hepatocarcinogenesis may involve multiple mutations with distinctive pathogenetic and clinicopathologic significance. To test this hypothesis, 68 cases of hepatocellular carcinoma (HCC) were studied prospectively for genetic-clinicopathologic correlation. Ten pathologic characteristics were evaluated. TP53 (alias p53) gene mutation was studied by a polymerase chain reaction (PCR)-single-strand conformation polymorphism-sequencing; CDKN2B (alias p15) and CDKN2A (alias p16) gene methylation by methylation-specific PCR; and genetic imbalances by comparative genomic hybridization (CGH). TP53 gene mutations occurred in 25% of cases, more than half being codon 249 G to T transversion. Methylation of CDKN2A was frequent (61.7%); of CDKN2B, rare (5.9%). The CGH analysis showed a median of nine aberrations per case, with amplifications more frequent than deletions. Isochromosomes might be involved in about 25% of cases. Amplifications of 1q and 8q were most frequent. Clinicopathologic correlations showed that CDKN2A methylation was significantly associated with tumors arising in cirrhotic livers; amplifications of 17q was significant in multiple parameters of tumor invasiveness (size, venous invasion, poor cellular differentiation, microsatellite formation); other amplifications (1q, 6p, 10p, and 20p) were also significant in tumor invasion; and deletions (at 1p, 11q, 4q, and 14q) were significant in tumor growth. Consistent patterns of genetic alterations were defined in HCC, which might represent distinctive pathways in hepatocarcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14499690     DOI: 10.1016/s0165-4608(03)00103-1

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  8 in total

Review 1.  Chromosome 6p amplification and cancer progression.

Authors:  Gda C Santos; M Zielenska; M Prasad; J A Squire
Journal:  J Clin Pathol       Date:  2006-06-21       Impact factor: 3.411

2.  Mutational Status of CDKN2A and TP53 Genes in Laryngeal Squamous Cell Carcinoma.

Authors:  Teodora A Todorova; Stanislav H Jordanov; Gergana S Stancheva; Ivan J Chalakov; Mincho B Melnicharov; Kuncho V Kunev; Vanio I Mitev; Radka P Kaneva; Teodora E Goranova
Journal:  Pathol Oncol Res       Date:  2014-08-23       Impact factor: 3.201

3.  TPX2 Level Correlates with Hepatocellular Carcinoma Cell Proliferation, Apoptosis, and EMT.

Authors:  Bo Liang; Chunhong Jia; Yu Huang; Hua He; Jialu Li; Hui Liao; Xiao Liu; Xincheng Liu; Xiaochun Bai; Dinghua Yang
Journal:  Dig Dis Sci       Date:  2015-05-30       Impact factor: 3.199

4.  Chromosome 6p Amplification in Aqueous Humor Cell-Free DNA Is a Prognostic Biomarker for Retinoblastoma Ocular Survival.

Authors:  Liya Xu; Ashley Polski; Rishvanth K Prabakar; Mark W Reid; Patricia Chevez-Barrios; Rima Jubran; Jonathan W Kim; Peter Kuhn; David Cobrinik; James Hicks; Jesse L Berry
Journal:  Mol Cancer Res       Date:  2020-05-20       Impact factor: 5.852

5.  Adenoviral gene therapy in hepatocellular carcinoma: a review.

Authors:  Iván Lyra-González; Laura Esther Flores-Fong; Ignacio González-García; David Medina-Preciado; Juan Armendáriz-Borunda
Journal:  Hepatol Int       Date:  2012-04-25       Impact factor: 6.047

6.  Predictive factors of microvascular invasion in patients with hepatocellular carcinoma larger than 5 cm.

Authors:  Yasuhiko Nagano; Hiroshi Shimada; Kazuhisa Takeda; Michio Ueda; Kenichi Matsuo; Kuniya Tanaka; Itaru Endo; Chikara Kunisaki; Shinji Togo
Journal:  World J Surg       Date:  2008-10       Impact factor: 3.352

Review 7.  Identification of drivers from cancer genome diversity in hepatocellular carcinoma.

Authors:  Atsushi Takai; Hien T Dang; Xin W Wang
Journal:  Int J Mol Sci       Date:  2014-06-20       Impact factor: 5.923

8.  CK19 and Glypican 3 Expression Profiling in the Prognostic Indication for Patients with HCC after Surgical Resection.

Authors:  Jiliang Feng; Ruidong Zhu; Chun Chang; Lu Yu; Fang Cao; Guohua Zhu; Feng Chen; Hui Xia; Fudong Lv; Shijie Zhang; Lin Sun
Journal:  PLoS One       Date:  2016-03-15       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.